Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.

Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer

Does the upside outweigh the downside for this pharma giant?

1 Green Flag for Eli Lilly Investors in 2022 -- and 1 Red Flag

Eli Lilly & Co. lly said Thursday it received a complete response letter (CRL) from the U.S. Food and Drug Administration regarding its Biologics License Application (BLA) for its treatment for non-small cell lung cancer. The CRL says the FDA can't approve the BLA for sintilimab in its present form, and includes a recommendation for an additional clinical study.

Eli Lilly's BLA for sintilimab can't be approved by FDA in present form

INDIANAPOLIS , March 24, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine sintilimab injection, a PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC). Sintilimab is being developed by Innovent Biologics, Inc. (HKEX: 01801) and Lilly.

Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

We understand that we are pulling the trigger here so soon after recommending it last week. But here's why.

Investing Club: This drug stock's rip-roaring rally was too good not to take some profits

Eli Lilly recently revealed encouraging results for the drug candidate mirikizumab in treating patients with moderately to severely active ulcerative colitis.

Could This Be Eli Lilly's Next Blockbuster Drug?

Deere & Company

Kroger

Many of these “boring” stocks have been outperforming thus far in 2022 and could continue trending higher over the next few months and beyond. It never hurts to look at companies that don't receive a lot of fanfare among investors

3 “Boring” Stocks to Consider Adding Now

AbbVie

Amgen

Bristol-Myers

Gilead Sciences

Merck

Pfizer

Walgreens

To say that hedge fund and mutual fund managers tend to follow the herd is an incredible understatement and always has been.

Fund Managers Pile Into Big Dividend Health Care Stocks: 8 ‘Strong Buy' Winners

PepsiCo

Walmart

Check out these defensive stocks amid slowing retail sales.

4 Defensive Stocks For Your Mid-March 2022 Watchlist

OXFORD, England & INGELHEIM, Germany & INDIANAPOLIS--(BUSINESS WIRE)--Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

The Independent Data Monitoring Committee recommended that the EMPA-KIDNEY trial be stopped early, following a formal interim assessment EMPA-KIDNEY is the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease to date Detailed results are expected to be presented later this year OXFORD, United Kingdom and RIDGEFIELD, Conn. and INDIANAPOLIS, March 16, 2022 /PRNewswire/ -- The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial's Independent Data Monitoring Committee.

Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

Eli Lilly and Company (LLY) Management Presents at Barclays Global Healthcare Conference Call Transcript

Eli Lilly's sales and earnings grew by double digits in 2021 due to its exceptional drug portfolio.

This Dividend Growth Stock Is a Screaming Buy

U.S. drugmaker Eli Lilly and Co said on Tuesday it would stop exporting non-essential medicines to Russia and no longer start new clinical studies in the country.

Lilly to stop exporting 'non-essential' drugs to Russia

Callon Petroleum

St. Joe

Although US crude oil futures traded sharply on Tuesday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced.

Executives Sell More Than $25M Of 4 Stocks

Adagene

Checkmate Pharmaceuticals

Gritstone Oncology Inc

Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association for Cancer Research Annual Meeting in New Orleans. Of the eight public companies that will discuss clinical trial results, half qualify as small caps or lesser.

Investors Hoping for News at Cancer Meeting That Will Boost Share Prices

INDIANAPOLIS, March 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from the pirtobrutinib and Verzenio® (abemaciclib) development programs will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, April 8 - 13, 2022. During the meeting, data will be presented from the BRUIN Phase 1b study of pirtobrutinib, an investigational, highly selective, non-covalent (reversible) BTK inhibitor, in combination with venetoclax with and without rituximab in relapsed/refractory chronic lymphocytic leukemia.

Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR)

Eli Lilly and Company (LLY) Presents at Cowen 42nd Annual Healthcare Conference (Transcript)

AstraZeneca

Sanofi

Can these health care stocks climb this month?

5 Health Care Stocks To Watch In March 2022

A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. LLY, -0.03% and Incyte Corp. INCY, -0.04% , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The new research, which was published Thursday in preprint form, meaning it's not peer-reviewed, came from the U.K.'s Recovery Trial.

Preliminary U.K. research says Lilly drug can reduce the risk of death among severely ill COVID-19 patients

INDIANAPOLIS, March 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 15, 2022. Patrik Jonsson, Lilly senior vice president, president of Lilly Immunology and Lilly USA, and chief customer officer, will participate in a fireside chat at 10:15 a.m.

Lilly to Participate in Barclays Global Healthcare Conference

IntriCon

Moderna

Novavax

Teladoc

Do these healthcare stocks pique your interest?

Stocks To Invest In Right Now? 5 Health Care Stocks For Your March Watchlist

RIDGEFIELD, Conn. and INDIANAPOLIS, March 1, 2022 /PRNewswire/ -- Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance® (empagliflozin) following stabilization and prior to discharge compared with placebo in the phase III EMPULSE trial, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial

INDIANAPOLIS, Feb. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Cowen Health Care Conference on Tuesday, March. 8, 2022. Anat Ashkenazi, Lilly senior vice president and chief financial officer, will participate in a virtual fireside chat at 10:30 a.m.

Lilly to Participate in Cowen Health Care Conference

The FDA approved Eli Lilly And Co (NYSE: LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients.

News for Eli Lilly Stock (LLY)